经核查独立董事李钟华女士、万勇先生、赵强先生的任职经历以 及签署的相关自查文件，上述人员未在公司担任除独立董事以外的任 何职务，也未在公司主要股东公司担任任何职务，与公司以及主要股 东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系， 不存在影响独立董事独立性的情况，符合相关法律法规及规范性文件 中对独立董事独立性的要求。 特此公告。 北京颖泰嘉和生物科技股份有限公司 证券代码：833819 证券简称：颖泰生物 公告编号：2024-009 北京颖泰嘉和生物科技股份有限公司 关于独立董事独立性自查情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律 责任。 根据中国证券监督管理委员会《上市公司独立董事管理办法》《北 京证券交易所股票上市规则（试行）》《北京证券交易所上市公司持续 监管指引第 1 号——独立董事》《公司章程》等要求，北京颖泰嘉和 生物科技股份有限公司（以下简称"公司"）董事会，就公司在任独 立董事李钟华女士、万勇先生、赵强先生的独立性情况进行评估并出 具如下专项意见： 董事会 20 ...

证券代码：833819 证券简称：颖泰生物 公告编号：2024-005 北京颖泰嘉和生物科技股份有限公司 第四届董事会第四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 24 日 2.会议召开地点：公司会议室 3.会议召开方式：现场会议与通讯会议相结合 4.发出董事会会议通知的时间和方式：2024 年 4 月 12 日以电话 及电子邮件方式发出 5.会议主持人：王榕 6.会议列席人员：全体监事 7.召开情况合法、合规、合章程性说明： 3.回避表决情况： 本议案不涉及关联交易事项，不需要回避表决。 会议的召集、召开和表决程序符合《中华人民共和国公司法》《公 司章程》及公司《董事会议事规则》的有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事张海安、于俊田、周曙光因公务以通讯方式出席了本次会议。 二、议案审议情况 （一）审议通过《董事会 2023 年度工作报告》 1.议 ...

证券代码：833819 证券简称：颖泰生物 公告编号：2024-010 北京颖泰嘉和生物科技股份有限公司 董事会审计委员会履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 北京颖泰嘉和生物科技股份有限公司（以下简称"公司"）董事会 审计委员会根据《公司章程》、《董事会审计委员会工作细则》等相关 规定和要求，在 2023 年度内勤勉尽责，积极开展工作。现将本年度 履职情况汇报如下： 一、基本情况 公司董事会审计委员会由 3 名不在公司担任高级管理人员的董事 组成，分别为赵强、万勇、张海安，其中赵强、万勇为公司独立董事， 张海安为公司董事，由具有会计专业资格的独立董事赵强担任审计委 员会召集人（主任）。 （1）监督及评估外部审计机构工作 报告期内，董事会审计委员会对公司聘请的财务报告审计机构四 川华信（集团）会计师事务所（特殊普通合伙）履行了监督职责，就 公司 2023 年年报审计工作计划听取了项目负责人的汇报，监督外部 审计机构按照计划开展年报审计工作。 （二）协调治理层、内部审计部门与外部审 ...

西南证券股份有限公司 关于北京颖泰嘉和生物科技股份有限公司 2023 年度募集资金存放与使用情况的专项核查报告 西南证券股份有限公司（以下简称"西南证券"、"保荐机构"）作为北京颖泰 嘉和生物科技股份有限公司（以下简称"颖泰生物"、"公司"）向不特定合格投资 者公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公 司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》《北京证券交易 所股票上市规则（试行）》《北京证券交易所证券发行上市保荐业务管理细则》《北 京证券交易所上市公司持续监管办法（试行）》以及《北京证券交易所上市公司 持续监管指引第 9 号—募集资金管理》等相关规定，对颖泰生物 2023 年度募集 资金存放与使用情况进行了专项核查，核查意见如下： 一、募集资金情况概述 （一）实际募集资金金额 2020 年 6 月 12 日，公司收到中国证券监督管理委员会（以下简称"中国证 监会"）《关于核准北京颖泰嘉和生物科技股份有限公司向不特定合格投资者公开 发行股票的批复》（证监许可[2020]1142 号），核准公司向不特定合格投资者公开 发行不超过 1 亿股新股，截至 2020 年 7 ...

证券代码：833819 证券简称：颖泰生物 公告编号：2024-011 北京颖泰嘉和生物科技股份有限公司 第四届监事会第四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 24 日 2.会议召开地点：公司会议室 3.会议召开方式：现场会议与通讯会议相结合 4.发出监事会会议通知的时间和方式：2024 年 4 月 12 日以电话 及电子邮件的方式发出 5.会议主持人：王剑 6.召开情况合法、合规、合章程性说明： 会议的召集、召开和表决程序符合《中华人民共和国公司法》《公 司章程》及公司《监事会议事规则》的有关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 监事王剑因公务以通讯方式参加了会议。 二、议案审议情况 （一）审议通过《监事会 2023 年度工作报告》 1.议案内容： 介绍 2023 年度监事会的主要工作情况。对公司 2023 年度的法人 治理情况、财务情况、关联交易情 ...

证券代码：833819 证券简称：颖泰生物 公告编号：2024-015 北京颖泰嘉和生物科技股份有限公司 关于 2023 年度募集资金存放与实际使用情况的专 项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 根据中国证监会发布的《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求（2022 年修订）》和北京证券交易 所颁布的《北京证券交易所股票上市规则（试行）》等有关规定，按 照北京颖泰嘉和生物科技股份有限公司（以下简称"公司"）制定的 《募集资金管理制度》相关要求，公司董事会编制了截至 2023 年 12 月 31 日募集资金存放与实际使用情况的专项报告。 一、募集资金基本情况 公司于 2020 年 2 月 13 日召开第二届董事会第十次会议、2020 年 2 月 28 日召开 2020 年第一次临时股东大会，审议通过了《关于申 请向不特定合格投资者公开发行股票并在精选层挂牌的方案的议 案》。 2020 年 6 月 12 日，北京颖泰嘉和生物科技股份有限公司（以下 简称"公司" ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥5.87 billion, a decrease of 28.09% compared to ¥8.16 billion in 2022[22]. - The net profit attributable to shareholders for 2023 was approximately ¥95.68 million, down 90.95% from ¥1.06 billion in 2022[22]. - The gross profit margin for 2023 was 17.12%, a decline from 26.04% in 2022[22]. - The net profit after deducting non-recurring gains and losses was approximately ¥49.20 million, a decrease of 95.43% compared to ¥1.08 billion in 2022[22]. - The basic earnings per share for 2023 was ¥0.08, down 90.70% from ¥0.86 in 2022[22]. - The weighted average return on net assets based on net profit attributable to shareholders was 1.63% in 2023, down from 19.59% in 2022[22]. - Net profit decreased by 91.38% to ¥3,370,210.53 in Q3 2023, down from ¥79,586,511.58 in Q2 2023[29]. - Operating income fell by 28.09% to ¥7,353,730,720.48 compared to ¥7,425,673,239.60 in the previous year[35]. - Cash flow from operating activities plummeted by 97.38% to ¥38,227,051.23 from ¥1,461,041,757.17[25]. - The interest coverage ratio dropped significantly to 1.82 from 7.39 in the previous year[25]. - The company's inventory turnover ratio decreased to 2.48 from 3.45 year-over-year[25]. - The company achieved revenue of ¥5,868,305,351.83, a decrease of ¥2,292,640,571.12 (approximately 28.1%) compared to the previous year's revenue of ¥8,160,945,922.95[51]. - The net profit attributable to shareholders was ¥95,683,463.98, down by ¥961,577,931.54 (approximately 91.0%) from ¥1,057,261,395.52 in the previous year[51]. - Main business revenue was CNY 5,774,742,867.41, a decrease of 28.14% compared to CNY 8,035,835,483.16 in the previous year[71]. Assets and Liabilities - Total assets increased by 0.72% to ¥12,642,144,017.44 compared to ¥12,551,314,670.01 in the previous year[25]. - Total liabilities rose by 3.55% to ¥6,853,604,881.19 from ¥6,618,844,117.47[25]. - Long-term borrowings increased by 303.74% to CNY 767.54 million, primarily to support project construction[64]. - The company has a total asset value of ¥12,642,144,017.44, an increase of ¥90,829,347.43 from the previous year[52]. Research and Development - The company is engaged in the research, production, and sales of pesticide intermediates, active ingredients, and formulations, as well as GLP registration services and biotechnology research and development[17]. - The company maintains a comprehensive business model focused on R&D and market demand in the agrochemical sector[38]. - The company collaborates closely with clients during the R&D process to meet customer requirements and expand its business[39]. - The company has established a mature independent innovation system with a focus on R&D, covering biotechnology, plant protection, and technical analysis, and has participated in several national key R&D projects[43]. - R&D expenditure for the current period amounted to ¥166,540,895.64, representing 2.84% of operating revenue, an increase from 2.57% in the previous period[102]. - The total number of R&D personnel increased from 492 to 548, with the proportion of R&D staff to total employees rising from 9.78% to 11.14%[104]. - The company holds a total of 383 patents, up from 350 in the previous period, including 196 invention patents, an increase from 177[105]. - The company is collaborating with Tianjin University on the development of new pesticide co-crystal products, providing research funding and technical materials[108]. - The company is also involved in a key national research project with Jiangsu Yangnong Chemical, focusing on the efficient green industrialization of new immune activators[108]. Market and Competition - The agricultural chemicals industry is expected to face continued downward pressure in the short term, but long-term demand for pesticides remains stable due to global food security needs[58]. - The company has maintained a stable market position, ranking among the top ten in China's pesticide sales for the past decade and within the top twenty globally for the last five years[60]. - The company is focusing on enhancing customer relationships and expanding its market presence through marketing transformation and supply chain integration[59]. - The company is actively expanding its market channels, particularly in the U.S. and Europe, through its partnership with ALBAUGH[94]. - The company has implemented strategies to address market competition and improve product profitability amidst industry challenges[95]. Environmental Responsibility - The company is committed to achieving carbon neutrality and sustainability goals, aligning its operations with national climate objectives[131]. - Environmental protection measures include compliance with pollution regulations and initiatives to reduce waste and emissions through process optimization and technology upgrades[130]. - The company has implemented measures to ensure compliance with the GB 39727-2020 standards for air pollutants[134]. - The company is focusing on continuous improvement in wastewater treatment processes to enhance environmental performance[134]. - The company has obtained environmental management system certification (GB/T24001-2016/ISO14001:2015) and maintains compliance with environmental regulations[150]. - The company has established an emergency response system for environmental incidents and conducted regular drills[156]. - The company has implemented a comprehensive wastewater treatment process, including physical and biochemical methods, achieving GB8978-1996 Class II standards[144]. Corporate Governance and Social Responsibility - The company has implemented a comprehensive internal control and governance structure to ensure compliance with relevant laws and regulations, enhancing operational transparency and investor relations[125]. - Employee welfare initiatives include flexible work hours, holiday bonuses, and health check-ups, alongside support for employees facing family hardships[126]. - The company has established a commercial ethics management system to protect the rights of suppliers and customers, fostering a fair and cooperative business environment[127]. - The company has actively participated in poverty alleviation and rural revitalization efforts, providing financial support for local infrastructure and healthcare, contributing to improved living standards in assisted villages[121]. - Subsidiaries have made charitable donations to local Red Cross and charity organizations, reinforcing the company's commitment to social responsibility[122]. Risk Management - The company faces risks related to shareholder control, governance, macroeconomic fluctuations, and tax policy changes, with specific countermeasures in place[172]. - The company is exposed to foreign exchange risks due to a significant portion of product sales being denominated in USD, and it has implemented measures to mitigate these risks[175]. - The company has established a risk-oriented internal management system to address environmental protection risks and has increased investment in environmental research and equipment[175]. - The company has established a comprehensive accident warning and handling mechanism to minimize the likelihood of safety incidents[175]. Future Strategies - The company aims to enhance agricultural production and ensure food security, focusing on sustainable development and core product competitiveness[163]. - From 2023 to 2024, the company emphasizes the necessity of strategic planning in response to challenging market conditions[164]. - The company plans to concentrate resources on core products and production bases to stabilize its operational foundation[165]. - Cost control measures will be implemented through technological innovation and lean production practices to optimize expenses[167]. - Organizational structure optimization will be pursued to enhance efficiency and employee engagement[168].

证券代码：833819 证券简称：颖泰生物 公告编号：2024-004 北京颖泰嘉和生物科技股份有限公司 关于使用闲置募集资金暂时补充流动资金归还的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律 责任。 北京颖泰嘉和生物科技股份有限公司（以下简称"公司"）于 2023 年 4 月 25 日召开了第三届董事会第二十三次会议、第三届监事会第 十七次会议，审议通过了《关于使用闲置募集资金暂时补充流动资金 的议案》，同意公司使用最高额度不超过人民币 10,000 万元的闲置募 集资金暂时补充流动资金，使用期限自公司董事会审议通过之日起不 超过 12 个月，到期前归还至募集资金专用账户。详细内容见公司于 2023 年 4 月 26 日在北京证券交易所指定信息披露平台披露的《关于 使用闲置募集资金暂时补充流动资金公告》（公告编号：2023-033）。 截至 2024 年 3 月 29 日，公司已将用于暂时补充流动资金的 10,000 万元募集资金全部归还并转入募集资金专用账户，使用期限 未超过 12 个月。公司已将上 ...

市场准入优势+转基因育种研究完成生产性试验，凸显公司核心竞争力 | --- | --- | --- | --- | --- | --- | |--------------------------------|-------|-------|-------|-------|-------| | 指标 | 2021A | 2022A | 2023E | 2024E | 2025E | | 营业收入 ( 百万元 ) | 7,426 | 8,161 | 5,905 | 6,956 | 7,961 | | YOY(%) | 19.3 | 9.9 | -27.6 | 17.8 | 14.5 | | 归母净利润 ( 百万元 ) | 476 | 1,057 | 95 | 200 | 405 | | YOY(%) | 46.4 | 121.9 | -91.0 | 110.0 | 103.0 | | 毛利率 (%) | 19.9 | 26.0 | 16.1 | 16.8 | 18.5 | | 净利率 (%) | 6.1 | 13.0 | 1.6 | 2.9 | 5.1 | | ROE(%) | 9.4 | 17.8 | 1.6 ...

Financial Performance - The company expects a net profit attributable to shareholders in the range of 90 million to 110 million CNY, representing a decrease of approximately 89.59% to 91.48% compared to the same period last year, where the profit was 1,056.89 million CNY[4]. - The decline in performance is attributed to factors such as a slowdown in downstream customer demand, industry destocking, and intensified market competition[5]. - The company's market sales scale has contracted, and product profitability has decreased year-on-year due to the adverse market conditions[6]. - The financial data presented is preliminary and has not been audited, with the final figures to be disclosed in the annual report[2][7].